Rznomics Inc, a South Korea based biopharmaceutical company, announced on Friday that the US Food and Drug Administration (FDA) has granted Fast Track Designation to the company's RZ-001 intended for the treatment of patients with Glioblastoma (GBM).
GBM is known as the most malignant tumour in Central Nervous system with high mortality rate but lacks effective therapies. RZ-001, the RNA replacement enzyme-based cancer gene therapy for the treatment of GBM, targets and cleaves hTERT mRNA and replaces the mRNA with the therapeutic gene RNA. This induces anti-cancer activity and cytotoxic effect by trans-ligating an HSVtk-encoding sequence into the reprogrammed hTERT mRNA. The company says that RZ-001 has demonstrated very promising responses in preclinical studies in which an enhanced anti-cancer efficacy and a higher survival rate was observed.
Rznomics received Phase I/IIa IND approval for RZ-001 from the FDA and the South Korean Ministry of Food and Drug Safety (MFDS) in Glioblastoma and the clinical trial will investigate the safety, tolerability, and efficacy of RZ-001 in patients with GBM. Subjects will be treated with RZ-001 according to the planned dose escalation design.
Anavex reports positive long-term data for blarcamesine in early Alzheimer's disease
Johnson & Johnson agrees acquisition of Intra-Cellular Therapies Inc
Neuraxpharm acquires Provigil and Nuvigil to expand CNS portfolio
Nuvation Bio secures NMPA approval for taletrectinib in China
JCR Pharmaceuticals and Modalis Therapeutics advance to next phase of joint gene therapy research
PTC Therapeutics submits vatiquinone NDA to US FDA
Mitsubishi Tanabe Pharma forms research collaboration with Dewpoint Therapeutics
IXICO signs commercial agreement with PETNET Solutions to enhance neuroimaging capabilities
Newron and EA Pharma sign licensing deal for Evenamide in Asia
Cybin selects Facet Life Sciences as US regulatory partner
GC Biopharma and Novel Pharma report first patient dosed in multinational trial of GC1130A
Merck's WELIREG approved in China for VHL disease
AbbVie signs new discovery, co-development and licence agreement with Gedeon Richter
JCR Pharmaceuticals showcases preclinical gene therapy advances at ESGCT Congress